Treatment of iron deficiency without anemia (latent iron deficiency) and iron deficiency anemia (clinically expressed iron deficiency). Iron deficiency and its degree should be confirmed by appropriate laboratory tests.
active substance: iron (in the form of a complex with polymaltose);
5 ml of syrup contains 50 mg of iron (in the form of a complex with polymaltose) (in terms of 100% dry matter);
auxiliary substances: methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), glycerin, sorbitol (E 420), sucrose, hydroxyethyl cellulose, vanilla-cream flavor (contains propylene glycol in an amount of not more than 1.5 mg / ml of syrup), purified water.
Ferumbo Dosage form
Basic physical and chemical properties: red-brown viscous liquid with a specific odor.
Ferumbo Pharmacotherapeutic group
Antianemic agents. Iron preparations (III) for oral administration. ATX code B03A B05.
The drug replenishes iron deficiency in the body, stimulates hemo- and erythropoiesis. During the course of treatment, it contributes to the rapid regression of clinical and laboratory symptoms of anemia. The complex of iron (III) hydroxide with polymaltose is stable, does not release iron in the form of free ions, and therefore does not have such side effects as irritation of the mucous membrane of the gastrointestinal tract, staining of teeth, metallic taste characteristic of iron (II) preparations. It is characterized by a high degree of safety. The transport of iron in the blood plasma is carried out with the help of transferrin gamma globulin, which is synthesized in the liver. Iron, in combination with transferrin, is transported into the cells of the body, where it is used for the synthesis of hemoglobin, myoglobin and some enzymes. The absorbed iron is retained as a bound compound with ferritin mainly in the liver. Ferric iron is involved in the formation of heme, which leads to an increase in hemoglobin levels. When using the drug, there is a gradual disappearance of clinical (weakness, fatigue, dizziness, tachycardia, dry skin) and laboratory symptoms of iron deficiency.
When ingested, iron from the polymaltose complex of iron (III) hydroxide is actively absorbed in the duodenum and small intestine (the greater the iron deficiency, the better its absorption). Active absorption of a preparation containing iron (III) excludes the development of an overdose, which is possible when simple iron (II) salts are absorbed along a concentration gradient. Iron, which is part of the complex of iron (III) hydroxide with polymaltose, does not possess the prooxidant properties that are inherent in simple iron (II) salts.
Treatment of iron deficiency without anemia (latent iron deficiency) and iron deficiency anemia (clinically significant iron deficiency).
Iron deficiency and its degree must be confirmed by appropriate laboratory tests.
Hypersensitivity to any component of the drug;
excess iron in the body (hemochromatosis, hemosiderosis);
anemia not caused by iron deficiency (eg, hemolytic anemia, megaloblastic anemia caused by vitamin B12 deficiency, aplastic anemia);
violation of iron utilization (anemia caused by lead poisoning, sideroblastic anemia, thalassemia);
esophageal stenosis and / or other obstructive diseases of the digestive tract; intestinal diverticulum, intestinal obstruction;
regular blood transfusions;
simultaneous use of parenteral forms of iron.
Interaction with other medicinal products and other types of interactions
Until now, the interaction of preparations of a complex of iron (III) hydroxide with polymaltose and other drugs and food products has not been reported. Animal studies using tetracycline, aluminum hydroxide, acetylsalicylic acid, sulfasalazine, calcium carbonate, calcium acetate, calcium phosphate together with vitamin D3, bromazepam, magnesium aspartate, D-penicillamine, methyldopa, paracetamol and auranofin showed no interaction with iron polymaltose complex (III).